Dyslipidemia is a key modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Current lipid-modifying therapies include statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors. These agents are used to improve lipid levels with a goal of CV risk reduction. Statins dominate the treatment paradigm owing to their good risk-benefit profile, evidence of CV benefits, and the availability of low-cost generic products. We expect recent positive cardiovascular outcomes trial (CVOT) data from certain nonstatin therapies, such as PCSK9 inhibitors and Vascepa, to influence the market penetration of these branded agents. Furthermore, the launches of novel therapies, including Novartis’s inclisiran and Esperion Therapeutics’ Nexletol / Nilemdo, will provide greater competition and drive market growth.
DRG’s Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 20 country-specific interviews with thought-leading lipidologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Prevalent cases of dyslipidemia by country, CVD prevention setting, and diagnosed/drug-treated populations.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key dyslipidemia therapies through 2030, segmented by brands/generics and CVD prevention setting.